Safety Dermatological Evaluation: Acceptability With Odontological Follow up - Cepacol Teen.

Single Site Study, Phase III, for Safety Dermatological Evaluation: Basic Acceptability With Odontological Follow up - Cepacol Teen.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00729599

Acronym

Cepacol Teen

Enrollment

Registered

2008-08-07

Start date

2008-07-31

Completion date

Unknown

Last updated

2009-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hygiene

Brief summary

To prove the safety, in normal conditions, of the Cepacol Teen, a formulation to odontological usage.

Interventions

DRUGCetylpyridinium chloride

Cetylpyridinium chloride during 21 consecutive days.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

10 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Integral buccal mucous (without oral pathologies); * Normal odontological exams;

Exclusion criteria

* Lactation or gestational risk or gestation; * Use of Antiinflammatory or immunosuppression drugs 15 days before the study; * Being in odontological treatment; * Pathological or mucous disease which can interfere or active gynaecological disease which may interfere wtih study results; * Personal history of allergic disease in the area to be treated; * Allergic or atopic history;

Design outcomes

Primary

Measure	Time frame
Patients will be evaluated according to the adverse reactions and the intensity of them.	21 days

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026